John Neis
Managing Director @ Venture Investors
Madison, United States
John Neis is a funding round investor at Venture Investors in Madison focused on Biotechnology and Health Care. John is managing director of Venture Investors, an early-stage venture capital firm focused on opportunities emerging from leading research universities in the Midwest.He currently serves on the Board of Directors at Cellectar, Inc., Deltanoid Pharmaceuticals, Inc., the Wisconsin Technology Council and is a science and technology advisor toWisconsin’s governor and legislature.He serves on the Dean’s Advisory Board, the Advisory Board of the Weinert Applied Ventures Program in the School of Business and the Tandem Press Advisory Board in the School of Education at the University of Wisconsin–Madison.He graduated Magna Cum Laude with a BS in finance from the University of Utah and received an MS in marketing and finance from the University of Wisconsin–Madison. He is a chartered financial analyst.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries John Neis invests in
Stages John Neis invests in
Countries John Neis invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 9 (53%)
- Health Care 7 (41%)
- Medical 4 (24%)
- Genetics 3 (18%)
- Life Science 3 (18%)
Stage
- Funding Round 5 (29%)
- Series A 4 (24%)
- Series B 3 (18%)
- Series D 2 (12%)
- Series C 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $30.4M / Series D / Sep 13, 2022 | |
Health Scholars
|
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VRsimulation, enabling users to get cost-effective and richer content experience. | $17M / Series B / Jan 16, 2020 | |
|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $39.5M / Series C / Sep 10, 2015 | |
Cellectar Biosciences
|
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $4M / Post-IPO Equity / Jan 01, 2014 | |
Inviragen
|
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 2.5 billion people across the globe. Inviragen is also developing a vaccine to protect against West Nile for the North Americanmarket, a nasal combination vaccine to protect against both plague and smallpox for biodefense, and a unique vaccine to protect against avian influenza for global markets. | $15M / Series A / Oct 06, 2009 | |
Deltanoid Pharmaceuticals
|
Deltanoid Pharmaceuticals Inc. is a privately funded biopharmaceutical company based in Madison, Wisconsin, engaged in research, development and commercialization of novel therapies for the treatment of human diseases. The company was founded to advance the development of raw university inventions, with an initial focus on vitamin D analogs andother compounds licensed from the Wisconsin Alumni Research Foundation. Deltanoid's continued focus is to develop selected therapies through early phases of the drug development process and seek partners for later stage development and commercialization in a wide variety of therapeutic areas, including renal disease, osteoporosis, and acne.Currently Deltanoid has a partnership agreement in place with Novadiol, Inc. for development of a vitamin D therapy. | $12M / Series B / Dec 18, 2007 | |
Roche NimbleGen
|
Roche NimbleGen provides products and services to the life science research market.The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow andorder different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents.The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services.Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG. | $12.8M / Series F / Nov 02, 2004 | |
|
Roche NimbleGen
|
Roche NimbleGen provides products and services to the life science research market.The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow andorder different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents.The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services.Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG. | $12.5M / Series D / Apr 17, 2003 | |
IntraLase
|
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means ofsurgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery.Theiradvanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc. | $22M / Oct 01, 2000 | |
Gala Biotech
|
Gala Biotech, a Catalent Pharma Solutions Company, was established in 1996 from technology developed at the University of Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company (currently over 40 employees, including 16 PhD’s) has a wide range of capabilities in the fields of molecular biology, vector biology, cell linedevelopment, biopharmaceutical manufacturing, protein biochemistry, and quality systems. Gala’s core proprietary technology is GPEx® (Gene Product Expression), a gene insertion/expression technology that allows rapid creation of stable, high-expressing mammalian cell lines for a wide variety of gene products."Gala" is Greek for milk, and the company's original mission was to produce pharmaceutical proteins in the milk of transgenic cows. The gene insertion technology that Gala developed to generate transgenic animals became the basis of Gala's Gene Product Expression or GPEx® technology for production of recombinant proteins in mammalian cell culture.The genomics revolution has led to the identification of thousands of new genes, and the race is now on to discover, characterize and stably express the protein products of these genes in order to develop new therapeutic proteins. Gala's GPEx® technology, when applied to mammalian cell culture, accelerates this process for its biopharmaceutical partners. Once new therapeutic proteins have been identified for clinical development, production support becomes a major challenge. Gala's mission is to meet this need, and the company has recently established a 43,000 square-foot facility in Middleton, Wisconsin devoted to GPEx®-based cell line development and cGMP-compliant protein production. | $10M / Jul 01, 2000 | |
| See all 17 investments → | |||
Co-Investors
About Venture Investors
Turning innovation into health. Venture Investors seeks the next big things in healthcare. Based in the Midwest with open access to renowned research universities, and the vibrant communities that surround them, we target, uncover, and invest in extraordinary ideas that will shape the future of health and wellness. With decades of proven success,we’re fueling the future of what’s driving healthcare. Today, we have over $200 million in assets under management.
Venture Investors Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Becky Hoerman
Controller
|
|||
David Arnstein
Chief Financial Officer and Managing Director
|
|||
Jake Simon
Principal Venture Partner
|
|||
Jim Adox
Managing Director
|
|||
|
John Neis
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does John Neis invest in?
John Neis invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact John Neis?
Public channels for John Neis include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did John Neis last invest?
The most recent investment recorded for John Neis closed in Sep 2022. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
